• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trial Listings
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Three Questions: Sean Stanton, Compass Research

Three Questions: Sean Stanton, Compass Research

June 27, 2016
CenterWatch Staff

CWWeekly presents this feature as a spotlight on issues faced by executives in clinical research. This week, writer Karyn Korieth spoke with Sean Stanton, CEO of Compass Research, which operates three research sites in central Florida. Compass Research was a finalist for the Society for Clinical Research Sites’ 2015 Site Patient Recruitment Innovation Award (SPRIA), which recognizes sites that employ innovative patient recruitment strategies.

Q: Tell us how you used free movie events to educate the community about clinical trials and help recruit volunteers for an Alzheimer’s-related study.

A: Compass Research con­ducted a study looking at the prevention of memory loss. To qualify, volunteers had to have a genetic marker, found in about two-to-five percent of the population, so we had to mass screen in order to find the right people. We wanted to create awareness among the healthy elderly population about clinical trials, and find a place where the type of person invested in stopping memory loss would congre­gate on a regular basis.

We hosted a movie event at no cost to pa­tients and their caregivers and showed “Still Alice,” which is about someone who develops early-onset Alzheimer’s disease. It gave us a platform to discuss the importance of early detection and research in finding a cure. There were some wor­ries about whether people would respond, but when the first movie ad ran, the spots were filled within the first hour. We had 200 people at the event, and more than 100 people indicated that they were interested in participating in the study. The study doctor, Craig Curtis, M.D., did a presen­tation before the movie, and when it ended he conducted a question-and-answer session.

The release of the “Still Alice” movie made it easy to discuss the study and the topic of Alzheimer’s. We planned other movie events geared to the senior population like “Women in Gold” and “The Second Best Marigold Hotel.” They received the same attendance response. Each week the theater location was changed to ensure new attendees were coming. For every movie, we did a presentation about clinical trials and had a question-and-answer session afterward. Our site is still utilizing this tactic and it continues to be successful.

Compass Research screened 3,000 volun­teers in the healthy elderly study over about 18 months, which was triple the goal. During the pre-screen assessment, we talked to them about how clinical trials can make a difference in the world and addressed their fears. If they were not eligible for the memory loss prevention study, some wanted to know about studies for another illness.

Q: You have been conducting clinical research for more than a decade. What is the best way to address the challenge of recruiting pa­tients for studies?

A: There is still not enough awareness about the benefits of clinical trials. It’s still a foreign topic to patients. If awareness about clinical research came from the primary care or treating physician, you would see a trust level that is significantly higher than what is seen direct-to-consumer. Patients seem to engage faster. We partner with about 45 physicians in our community to make sure that they are aware of the benefits we can provide to their patients. Our outreach and partnerships in the community have become very important. The physicians have the patients and the records. By partnering with them, screen-fail rates can decrease.

We still perform direct-to-consumer recruit­ment for some populations. Trying to find thou­sands of people over the course of 18 months is a different initiative than using day-to-day practices. But our initiatives are moving toward creating networks in the community. To me, that’s the key. If we are recruiting for an Alzheimer’s trial that needs 20 patients, partnerships in the community become the most important piece for successful recruitment.

Most doctors choose medicine as a career because of the science involved, but when they move into daily practice, the science component is often lost. When we connect with doctors to bring science back into practice, they are extremely excited. The best partners are the doctors who are strong patient advocates with a flair for science.

Q: Are there specific ways that CROs and sponsors could better support sites in patient recruitment efforts?

A: There is always room for improvement. We need to communicate and test innovative ways of recruiting because it’s always evolving. Sometimes we operate in our own lanes and the site, CRO and sponsor don’t communicate enough about what may or may not be working effectively. I would like for us to get together earlier in the study process to look at the best ways to recruit for the individual trial before the protocol is finalized. Sometimes the site, CRO and sponsor have already outsourced to a recruitment firm and haven’t talked to us about the best way to recruit for a specific popula­tion. We just get handed their recruitment plan while we are running our own plan. There is no collaboration.

If we could communicate earlier in the recruit­ment strategy process it could be advantageous for everyone. If there is agreement to the plan in advance—and if it fails—there isn’t any finger-pointing.

 

This article was reprinted from Volume 20, Issue 25, of CWWeekly, a leading clinical research industry newsletter providing expanded analysis on breaking news, study leads, trial results and more. Subscribe »

Upcoming Events

  • 12Apr

    The Participant Playbook Webinar Series, Part 3 — Rethinking the Development of Participant-Centric Clinical Trial Technology

  • 25Apr

    Effective Root Cause Analysis and CAPA Investigations for Drugs, Devices and Clinical Trials

  • 26Apr

    FDA’s New Laws and Regulations: What Drug and Biologics Manufacturers Need to Know

  • 27Apr

    Califf’s FDA, 2023 and Beyond: Key Developments, Insights and Analysis

  • 17May

    2023 WCG Avoca Quality Consortium Summit

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Five Ws

    Consider the Five ‘W’s to Understand Potential Participants

  • QandA-360x240.png

    Perspectives from Smaller-Sized CROs: Q&A with Cheryle Evans

  • White House

    Trial Stakeholders Advise White House on Emergency Research Infrastructure

  • SurveywBlueBackground-360x240.png

    Stress Levels Continue to Climb in Healthcare Workforce, Survey Finds

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing